Michael Trang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael Trang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Sujata M. Bhavnani
Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA
8 shared publications - Christopher M. Rubino
Institute for Clinical Pharmacodynamics
5 shared publications - Paul G. Ambrose
Institute for Clinical Pharmacodynamics
5 shared publications J. P. Hammel
Institute for Clinical Pharmacodynamics, Schenectady, New York, USA
3 shared publications- Brian D. VanScoy
Institute for Clinical Pharmacodynamics, Schenectady, New York, USA
2 shared publications E. A. Lakota
Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA
2 shared publications
Latest Publications
- Open Access
- 4 September 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (9) , e0128123
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections
Pharmacokinetic-pharmacodynamic (PK-PD) relationships for efficacy were evaluated using data from omadacycline-treated patients with acute bacterial skin and skin structure infections (ABSSSI) enrolled in two phase 3 studies. Patients received omadacycline 100 mg intravenously (IV) every 12 hours for two doses, followed by 100 mg IV every 24 hours (q24h), with the option to switch to 300 mg oral (PO) q24h after 3 days or 450 mg PO q24h for two doses, followed by 300 mg PO q24h for a total duration of 7–14 days. Clinical response was evaluated at 48–72 hours [early clinical response (ECR)], end of treatment (EOT), and 7–14 days after EOT. Using a population pharmacokinetic (PK) model and PK data from patients with Staphylococcus aureus at baseline, omadacycline free-drug plasma area under the concentration-time curve (AUC) values were determined, and the relationships between free-drug plasma AUC:MIC ratio and dichotomous efficacy endpoints were evaluated. Using these relationships, the population PK model, simulation, and an omadacycline MIC distribution for S. aureus , mean percent probabilities of response were evaluated. Statistically significant PK-PD relationships were identified for ECR ( P = 0.016 and 0.013 for optimized two- and three-group free-drug plasma AUC:MIC ratios, respectively). At an MIC value of 0.5 µg/mL, percent probabilities of model-predicted success for ECR based on the univariable PK-PD relationships using continuous and two-group free-drug plasma AUC:MIC ratio variables were 91.9 and 95.6%, respectively, for the IV-to-PO dosing regimen and 89.3 and 88.4%, respectively, for the PO-only dosing regimen. These data support for omadacycline IV-to-PO and PO-only dosing regimens for ABSSSI and an omadacycline susceptibility breakpoint of 0.5 µg/mL for S. aureus .
- 4 September 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (9) , e0128123
Open AccessAssessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections
Pharmacokinetic-pharmacodynamic (PK-PD) relationships for efficacy were evaluated using data from omadacycline-treated patients with acute bacterial skin and skin structure infections (ABSSSI) enrolled in two phase 3 studies. Patients received omadacycline 100 mg intravenously (IV) every 12 hours for two doses, followed by 100 mg IV every 24 hours (q24h), with the option to switch to 300 mg oral (PO) q24h after 3 days or 450 mg PO q24h for two doses, followed by 300 mg PO q24h for a total duration of 7–14 days. Clinical response was evaluated at 48–72 hours [early clinical response (ECR)], end of treatment (EOT), and 7–14 days after EOT. Using a population pharmacokinetic (PK) model and PK data from patients with Staphylococcus aureus at baseline, omadacycline free-drug plasma area under the concentration-time curve (AUC) values were determined, and the relationships between free-drug plasma AUC:MIC ratio and dichotomous efficacy endpoints were evaluated. Using these relationships, the population PK model, simulation, and an omadacycline MIC distribution for S. aureus , mean percent probabilities of response were evaluated. Statistically significant PK-PD relationships were identified for ECR ( P = 0.016 and 0.013 for optimized two- and three-group free-drug plasma AUC:MIC ratios, respectively). At an MIC value of 0.5 µg/mL, percent probabilities of model-predicted success for ECR based on the univariable PK-PD relationships using continuous and two-group free-drug plasma AUC:MIC ratio variables were 91.9 and 95.6%, respectively, for the IV-to-PO dosing regimen and 89.3 and 88.4%, respectively, for the PO-only dosing regimen. These data support for omadacycline IV-to-PO and PO-only dosing regimens for ABSSSI and an omadacycline susceptibility breakpoint of 0.5 µg/mL for S. aureus .
- Open Access
- 18 April 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (4) , e0221321
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae
Omadacycline, a novel aminomethylcycline with in vitro activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae , is approved in the United States to treat patients with community-acquired bacterial pneumonia (CABP). Using nonclinical pharmacokinetic-pharmacodynamic (PK-PD) targets for efficacy and in vitro surveillance data for omadacycline against S. pneumoniae and H. influenzae , and a population pharmacokinetic model, PK-PD target attainment analyses were undertaken using total-drug epithelial lining fluid (ELF) and free-drug plasma exposures to evaluate omadacycline 100 mg intravenously (i.v.) every 12 h or 200 mg i.v. every 24 h (q24h) on day 1, followed by 100 mg i.v. q24h on day 2 and 300 mg orally q24h on days 3 to 5 for patients with CABP.
- 18 April 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (4) , e0221321
Open AccessPharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae
Omadacycline, a novel aminomethylcycline with in vitro activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae , is approved in the United States to treat patients with community-acquired bacterial pneumonia (CABP). Using nonclinical pharmacokinetic-pharmacodynamic (PK-PD) targets for efficacy and in vitro surveillance data for omadacycline against S. pneumoniae and H. influenzae , and a population pharmacokinetic model, PK-PD target attainment analyses were undertaken using total-drug epithelial lining fluid (ELF) and free-drug plasma exposures to evaluate omadacycline 100 mg intravenously (i.v.) every 12 h or 200 mg i.v. every 24 h (q24h) on day 1, followed by 100 mg i.v. q24h on day 2 and 300 mg orally q24h on days 3 to 5 for patients with CABP.
- 18 April 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (4) , e0145222
Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches
Acinetobacter baumannii- Acinetobacter calcoaceticus complex (referred to herein as A. baumannii ) treatment guidelines contain numerous older antimicrobial agents with susceptibility test interpretive criteria (STIC, also known as susceptibility breakpoints) set using only epidemiological data. We utilized a combination of in vitro surveillance data, preclinical murine thigh and lung infection models, population pharmacokinetics, simulation, and pharmacokinetic/pharmacodynamic (PK/PD) target attainment analyses to evaluate A. baumannii STIC for four commonly recommended antimicrobials from different classes (amikacin, ceftazidime, ciprofloxacin, and minocycline).
- 18 April 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (4) , e0145222
Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches
Acinetobacter baumannii- Acinetobacter calcoaceticus complex (referred to herein as A. baumannii ) treatment guidelines contain numerous older antimicrobial agents with susceptibility test interpretive criteria (STIC, also known as susceptibility breakpoints) set using only epidemiological data. We utilized a combination of in vitro surveillance data, preclinical murine thigh and lung infection models, population pharmacokinetics, simulation, and pharmacokinetic/pharmacodynamic (PK/PD) target attainment analyses to evaluate A. baumannii STIC for four commonly recommended antimicrobials from different classes (amikacin, ceftazidime, ciprofloxacin, and minocycline).
- Open Access
- 18 April 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (4) , e0239721
Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients stratified by comorbidities.
- 18 April 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (4) , e0239721
Open AccessEvaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients stratified by comorbidities.
- Open Access
- 24 January 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (1) , e0220121
Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia
- 24 January 2023
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 67 (1) , e0220121
Open AccessOmadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia
- Open Access
- 20 December 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (12) , e0213021
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
Meropenem-vaborbactam is a fixed-dose beta-lactam/beta-lactamase inhibitor with potent in vitro and in vivo activity against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales . Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses were undertaken using population pharmacokinetic models, nonclinical PK-PD targets for efficacy, in vitro surveillance data, and simulation to provide support for 2 g meropenem-2 g vaborbactam every 8 h (q8h) administered as a 3-h intravenous (i.v.) infusion, and dosing regimens adjusted for patients with renal impairment.
- 20 December 2022
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (12) , e0213021
Open AccessPharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
Meropenem-vaborbactam is a fixed-dose beta-lactam/beta-lactamase inhibitor with potent in vitro and in vivo activity against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales . Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses were undertaken using population pharmacokinetic models, nonclinical PK-PD targets for efficacy, in vitro surveillance data, and simulation to provide support for 2 g meropenem-2 g vaborbactam every 8 h (q8h) administered as a 3-h intravenous (i.v.) infusion, and dosing regimens adjusted for patients with renal impairment.
- Open Access
- 17 August 2021
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (9) , AAC0260620
Population Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
Meropenem-vaborbactam is a broad-spectrum carbapenem–beta-lactamase inhibitor combination approved in the United States and Europe to treat patients with complicated urinary tract infections and in Europe for other serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia. Population pharmacokinetic (PK) models were developed to characterize the time course of meropenem and vaborbactam using pooled data from two phase 1 and two phase 3 studies.
- 17 August 2021
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (9) , AAC0260620
Open AccessPopulation Pharmacokinetics of Meropenem and Vaborbactam Based on Data from Noninfected Subjects and Infected Patients
Meropenem-vaborbactam is a broad-spectrum carbapenem–beta-lactamase inhibitor combination approved in the United States and Europe to treat patients with complicated urinary tract infections and in Europe for other serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia. Population pharmacokinetic (PK) models were developed to characterize the time course of meropenem and vaborbactam using pooled data from two phase 1 and two phase 3 studies.
- Open Access
- 4 October 2017
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 4 (suppl_1) , S530-S531
Meropenem–Vaborbactam Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses as Support for Dose Selection in Patients with Normal Renal Function and Varying Degrees of Renal Impairment
Meropenem-vaborbactam is a broad-spectrum carbapenem-β-lactamase inhibitor combination that is being developed to treat patients with serious gram-negative infections, including those caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae (ENT). PK-PD target attainment analyses were undertaken using Monte Carlo simulation, population PK models, non-clinical PK-PD targets for efficacy, and in vitro surveillance data to provide meropenem-vaborbactam dose selection. Four simulated patient populations (n = 1000 each) varying by creatinine clearance (CLcr) were generated. Using meropenem and vaborbactam population PK models [Trang M et al. Microbe 2017, P2118], individual post-hoc parameter estimates were generated. Using these estimates, total-drug concentration-time profiles were generated for simulated patients with CLcr of ≥40–150 mL/minute, ≥20 to 40 mL/minute, ≥10 to 20 mL/minute, and ≥0 to 10 mL/minute who received meropenem-vaborbactam 2 g – 2 g q8h, 1 g – 1 g q8h, 1 g – 1 g q12h, 500 mg–500 mg q12h, respectively, as a 3-hour infusion. Using protein binding estimates (2 and 33%, respectively), Day 1 free-drug meropenem %T>MIC and vaborbactam AUC:MIC ratio were calculated. Percent probabilities of achieving meropenem %T>MIC targets of 30, 35 and 45% associated with net bacterial stasis, and 1- and 2-log10 CFU reductions from baseline, respectively, and the ratio of vaborbactam AUC to meropenem-vaborbactam MIC associated with net bacterial stasis were evaluated. An algorithm to assess PK-PD target attainment at meropenem and corresponding meropenem-vaborbactam MIC values based on in vitro surveillance data for ENT and KPC-producing ENT was followed. For P. aeruginosa, meropenem %T>MIC targets alone were assessed relative to meropenem-vaborbactam MIC values. Figures 1 to 3 show high percent probabilities of PK-PD target attainment at or above the upper margins of meropenem-vaborbactam MIC distributions for ENT, KPC-producing ENT, P. aeruginosa were observed across all renal function groups. These data provide support for meropenem 2 g–vaborbactam 2 g q8h administered as a 3-hour infusion and adjusted dosage regimens for patients with varying degrees of renal impairment. S. M. Bhavnani, The Medicines Company: Research Contractor, Research support; M. Trang, The Medicine’s Company: Research Contractor, Research support; D. C. Griffith, The Medicine’s Company: Employee and Shareholder, Salary; O. Lomovskaya, The Medicine’s Company: Employee and Shareholder, Salary; J. P. Hammel, The Medicine’s Company: Research Contractor, Research support; J. S. Loutit, The Medicine’s Company: Employee and Shareholder, Salary; M. N. Dudley, The Medicine’s Company: Employee and Shareholder, Salary; P. G. Ambrose, The Medicine’s Company: Research Contractor, Research support; C. M. Rubino, The Medicine’s Company: Research Contractor, Research support.
- 4 October 2017
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 4 (suppl_1) , S530-S531
Open AccessMeropenem–Vaborbactam Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses as Support for Dose Selection in Patients with Normal Renal Function and Varying Degrees of Renal Impairment
Meropenem-vaborbactam is a broad-spectrum carbapenem-β-lactamase inhibitor combination that is being developed to treat patients with serious gram-negative infections, including those caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae (ENT). PK-PD target attainment analyses were undertaken using Monte Carlo simulation, population PK models, non-clinical PK-PD targets for efficacy, and in vitro surveillance data to provide meropenem-vaborbactam dose selection. Four simulated patient populations (n = 1000 each) varying by creatinine clearance (CLcr) were generated. Using meropenem and vaborbactam population PK models [Trang M et al. Microbe 2017, P2118], individual post-hoc parameter estimates were generated. Using these estimates, total-drug concentration-time profiles were generated for simulated patients with CLcr of ≥40–150 mL/minute, ≥20 to 40 mL/minute, ≥10 to 20 mL/minute, and ≥0 to 10 mL/minute who received meropenem-vaborbactam 2 g – 2 g q8h, 1 g – 1 g q8h, 1 g – 1 g q12h, 500 mg–500 mg q12h, respectively, as a 3-hour infusion. Using protein binding estimates (2 and 33%, respectively), Day 1 free-drug meropenem %T>MIC and vaborbactam AUC:MIC ratio were calculated. Percent probabilities of achieving meropenem %T>MIC targets of 30, 35 and 45% associated with net bacterial stasis, and 1- and 2-log10 CFU reductions from baseline, respectively, and the ratio of vaborbactam AUC to meropenem-vaborbactam MIC associated with net bacterial stasis were evaluated. An algorithm to assess PK-PD target attainment at meropenem and corresponding meropenem-vaborbactam MIC values based on in vitro surveillance data for ENT and KPC-producing ENT was followed. For P. aeruginosa, meropenem %T>MIC targets alone were assessed relative to meropenem-vaborbactam MIC values. Figures 1 to 3 show high percent probabilities of PK-PD target attainment at or above the upper margins of meropenem-vaborbactam MIC distributions for ENT, KPC-producing ENT, P. aeruginosa were observed across all renal function groups. These data provide support for meropenem 2 g–vaborbactam 2 g q8h administered as a 3-hour infusion and adjusted dosage regimens for patients with varying degrees of renal impairment. S. M. Bhavnani, The Medicines Company: Research Contractor, Research support; M. Trang, The Medicine’s Company: Research Contractor, Research support; D. C. Griffith, The Medicine’s Company: Employee and Shareholder, Salary; O. Lomovskaya, The Medicine’s Company: Employee and Shareholder, Salary; J. P. Hammel, The Medicine’s Company: Research Contractor, Research support; J. S. Loutit, The Medicine’s Company: Employee and Shareholder, Salary; M. N. Dudley, The Medicine’s Company: Employee and Shareholder, Salary; P. G. Ambrose, The Medicine’s Company: Research Contractor, Research support; C. M. Rubino, The Medicine’s Company: Research Contractor, Research support.